-

Dr. Mark Stetter Elected to Zoetis Board of Directors

Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025.

Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board’s Quality and Innovation Committee.

“Dr. Stetter brings invaluable real-world experience in animal health to our Board,” said Kristin Peck, Chief Executive Officer of Zoetis. “Our customers are at the heart of everything we do and leveraging Mark’s experiences and insights will help us continue to adapt and innovate to best serve them. We’re thrilled to have him join our Board as we continue to live our purpose of advancing care for animals.”

“We are pleased to welcome Dr. Mark Stetter to Zoetis’ Board of Directors, and we look forward to the contributions he will make as we continue to advance the animal health industry and deliver innovation to our customers,” said Zoetis Board Chair Michael McCallister.

Dr. Stetter has served as Dean of the University of California, Davis School of Veterinary Medicine since 2021. In this role he oversees all aspects of the school including education, research, veterinary hospitals, animal health diagnostic labs, centers and institutes. He was Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021. Prior to joining higher education, Dr. Stetter held various roles at The Walt Disney Company, The Bronx Zoo/Wildlife Conservation Society and the Audubon Nature Institute. Dr. Stetter holds a Doctor of Veterinary Medicine and a Bachelor of Science degree in biochemistry and chemistry from the University of Illinois at Champaign-Urbana.

“I am incredibly grateful for the opportunity to join Zoetis’ Board of Directors,” said Dr. Mark Stetter. “As a veterinarian I've seen firsthand the impact the company’s innovative products have on animals, and I look forward to bringing my professional expertise and passion for animal health to Zoetis as they continue to advance care for the industry.”

About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

ZTS-COR

ZTS-IR

Contacts

Media:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Declares Third Quarter 2025 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After in...

Zoetis to Participate in Upcoming Investor Conferences

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m. CT Investors and other interested parties can access live audio webcasts of the presentations by visiting http://invest...

Zoetis Announces First Quarter 2025 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024. Net income for the first quarter of 2025 was $631 million, or $1.41 per...
Back to Newsroom